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Abstract
© 2016,  Springer  Science+Business  Media  New  York.Genome  editing  approach  based  on
prokaryotic  CRISPR (clustered regularly  interspaced short  palindromic repeats)  system is  a
simple and useful way to investigate gene functions on a genome-wide scale. It is especially
important  for  cancer  research because of  genetic  contribution  to  tumor  development.  We
applied this  technique in  a  high-throughput  screening format  to  find genes that  could  be
involved in chemotherapy resistance of pancreatic cancer. We used AsPC1 cell line expressing
doxycycline-inducible Cas9 to screen two sgRNA lentiviral libraries: (1) cell cycle genes (CC, 983
genes, ∼12,000 sgRNA) and (2) genome-wide (GW, ∼90,000 sgRNA). These sets of cells with
different gene knockouts were treated with oxaliplatin to identify knockouts which increase
sensitivity to the drug. We have performed screening both in vitro and in vivo settings. For the
in  vivo  arm  of  our  experiments,  peritoneal  carcinomatosis  model  in  severe  combined
immunodeficiency (SCID) mice was created by intraperitoneal  injection of  AsPC1/Cas9 cells
infected with sgRNA library. Genomic DNA from cells and animal tumor material was analyzed
using  next  generation  sequencing  (NGS)  to  obtain  data  about  representation  of  sgRNA.
Preliminary data allowed us to identify genes potentially modulating oxaliplatin sensitivity.
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